Teligent, Inc. (NASDAQ:TLGT) had its target price lowered by equities research analysts at Deutsche Bank AG from $9.00 to $8.00 in a research note issued on Monday. The brokerage currently has a “hold” rating on the stock. Deutsche Bank AG’s price objective points to a potential upside of 24.61% from the company’s current price.

A number of other analysts have also commented on the stock. Zacks Investment Research lowered shares of Teligent from a “hold” rating to a “sell” rating in a report on Thursday, July 6th. BidaskClub lowered shares of Teligent from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 1st. Canaccord Genuity initiated coverage on shares of Teligent in a report on Monday, July 31st. They set a “buy” rating and a $11.00 target price for the company. ValuEngine lowered shares of Teligent from a “hold” rating to a “sell” rating in a report on Tuesday, July 25th. Finally, Roth Capital set a $9.00 target price on shares of Teligent and gave the stock a “buy” rating in a report on Wednesday, August 9th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $9.00.

Teligent (TLGT) traded up 1.71% on Monday, hitting $6.53. The company had a trading volume of 75,431 shares. The firm’s 50 day moving average price is $8.29 and its 200 day moving average price is $8.00. Teligent has a 12-month low of $5.74 and a 12-month high of $9.54. The stock’s market cap is $348.64 million.

Teligent (NASDAQ:TLGT) last released its earnings results on Tuesday, August 8th. The company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by $0.04. Teligent had a positive return on equity of 1.49% and a negative net margin of 11.36%. The business had revenue of $18.40 million for the quarter, compared to analyst estimates of $20.11 million. During the same period in the prior year, the firm posted $0.02 EPS. Teligent’s revenue was up 7.4% on a year-over-year basis. Equities analysts predict that Teligent will post $0.12 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Teligent, Inc. (NASDAQ:TLGT) Price Target Cut to $8.00 by Analysts at Deutsche Bank AG” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/14/teligent-inc-nasdaqtlgt-price-target-cut-to-8-00-by-analysts-at-deutsche-bank-ag.html.

Several institutional investors have recently made changes to their positions in TLGT. American International Group Inc. boosted its position in shares of Teligent by 7.1% in the first quarter. American International Group Inc. now owns 25,488 shares of the company’s stock worth $199,000 after buying an additional 1,680 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its position in shares of Teligent by 19.7% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 48,030 shares of the company’s stock worth $375,000 after buying an additional 7,897 shares in the last quarter. Eagle Global Advisors LLC purchased a new position in shares of Teligent during the first quarter worth $309,000. Teza Capital Management LLC purchased a new position in shares of Teligent during the first quarter worth $116,000. Finally, UBS Asset Management Americas Inc. purchased a new position in shares of Teligent during the first quarter worth $170,000. 62.88% of the stock is currently owned by institutional investors.

Teligent Company Profile

Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.

Receive News & Ratings for Teligent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.